Palvella Therapeutics (PVLA) Cash & Equivalents (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Cash & Equivalents for 14 consecutive years, with $206.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 172.91% year-over-year to $206.4 million; the TTM figure through Mar 2026 stood at $206.4 million (up 172.91% YoY), while the FY2025 annual figure was $58.0 million, down 30.65% from the prior year.
• Cash & Equivalents improved to $206.4 million in Q1 2026 per PVLA's latest filing, from $58.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $206.4 million in Q1 2026 and bottomed at $6.2 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $58.5 million across 5 years, with a median of $54.9 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 87.09% — and 2025, when it jumped 1110.4%.
• Palvella Therapeutics' Cash & Equivalents stood at $38.6 million in 2022, then sank by 80.98% to $7.4 million in 2023, then surged by 1037.44% to $83.6 million in 2024, then slumped by 30.65% to $58.0 million in 2025, then jumped by 255.96% to $206.4 million in 2026.
• Business Quant data shows PVLA's Cash & Equivalents at $206.4 million in Q1 2026, $58.0 million in Q4 2025, and $63.6 million in Q3 2025.